Skip to main content

Table 3 HEAs (Hit Enriched Assays) from lymphangiogenesis hits

From: CSgator: an integrated web platform for compound set analysis

Rank Assay title Target
gene
Enrichment score of HEA Number of hit/assayed compounds FDR-adjusted p value PubChem AID
(year)
Reference
1 Inhibitors of regulator of G protein signaling (RGS) 4 RGS4 9.63 152/390,220 3.40E−16 504,845 (2011) [38, 39]
2 Validation screen for inhibitors of Lassa infection 7.18 54/1279 3.04E−13 463,096 (2010)  
3 High content imaging cell-Based qHTS for inhibitors of the mTORC1 signaling pathway in MEF (Tsc2-/-, p53-/-) cells MTOR 7.12 23/1280 8.03E−09 2666 (2010) [40, 41]
4 Validation screen for small molecules that induce DNA re-replication in MCF 10A normal breast cells GMNN 6.77 71/1280 4.61E−11 463,097 (2010)  
5 High content imaging cell-based qHTS for inhibitors of the mTORC1 signaling pathway in MEF cells MTOR 6.35 52/1280 1.85E−10 2667 (2010) [40, 41]
6 Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1 ATAD5 6.22 79/1280 3.78E−10 493,107 (2011)  
7 qHTS assay for identification of small molecule antagonists for thrombopoietin (TPO) signaling pathway THPO 6.21 122/1277 1.11E−08 918 (2010) [42, 43]
8 qHTS for inhibitors of ATXN expression: validation ATXN2 5.94 73/1280 2.67E−07 588,378 (2011)  
9 qHTS assay for the inhibitors of human flap endonuclease 1 (FEN1) FEN1 5.87 1368/391,275 2.04E−07 588,795 (2011)  
10 AP1 signaling pathway AP1 5.85 55/10,692 4.90E−5 357 (2006) [44, 45]